Travere Therapeutics, Inc. (TVTX)
Automate Your Wheel Strategy on TVTX
With Tiblio's Option Bot, you can configure your own wheel strategy including TVTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVTX
- Rev/Share 3.0958
- Book/Share 0.3715
- PB 38.7902
- Debt/Equity 12.2007
- CurrentRatio 2.0507
- ROIC -0.5142
- MktCap 1279677168.0
- FreeCF/Share -1.9836
- PFCF -7.3015
- PE -5.616
- Debt/Assets 0.7297
- DivYield 0
- ROE -11.8397
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | TVTX | Citigroup | -- | Buy | $35 | $32 | June 11, 2025 |
| Resumed | TVTX | H.C. Wainwright | -- | Buy | -- | $30 | June 11, 2025 |
| Initiation | TVTX | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 10, 2025 |
| Upgrade | TVTX | Wells Fargo | Equal Weight | Overweight | $9 | $27 | Oct. 21, 2024 |
| Initiation | TVTX | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Upgrade | TVTX | Guggenheim | Neutral | Buy | -- | $25 | Sept. 9, 2024 |
News
Travere (TVTX) Moves 12.6% Higher: Will This Strength Last?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has completed its Type C meeting …
Read More
About Travere Therapeutics, Inc. (TVTX)
- IPO Date 2012-11-08
- Website https://www.travere.com
- Industry Biotechnology
- CEO Dr. Eric M. Dube Ph.D.
- Employees 385